1999, since the establishment of the synthesis research team in 1999, with the goal of import substitution and overseas market expansion. We have been actively developing synthetic technologies for raw pharmaceutical materials.

As a result, in 1999, we successfully developed the synthesis technology for PPI (Proton Pump Inhibitor) including Lansoprazole, a therapeutic agent for peptic ulcer and reflux esophagitis, and started producing it in-house, replacing imports. In 2000, we launched and commercialized Clarithromycin, a macrolide antibiotics against Helicobacter Pylori. In 2001, we developed the synthesis technology for Allyamine, antifungal agent.
Based on the self-production technology for raw pharmaceutical materials, this has provided an opportunity to replace imports and further develop independent marketing strategies in the global market.

In the future, we plan to continue our efforts in developing new synthesis technologies for competitive finished pharmaceutical products in the global market, and for optically active pharmaceuticals and intermediates, which are expected to have high market demand in the future.